

## Author Index

(Page numbers in italics refer to abstracts)

### A

Abe T, 688  
 Abraham GN, 134, 135  
 Adams LE, 217  
 Agarwal A, 525  
 Aidem HP, 532  
 Alarcon-Segovia D, 776  
 Alea JA, 549  
 Alepa FP, 132  
 Allen FH Jr, 573  
 Altman RD, 113, 129, 171, 179  
 Amstutz HC, 533  
 Anderson CH, 114  
 Anderson L, 122  
 Andreis M, 121, 572  
 Andrews R, 136  
 Angevine CD, 102, 278  
 Ansell BM, 130, 281  
 Aptekar RG, 446, 461, 533, 572, 715  
 Arnett FC, 546  
 Arnold PI, 131  
 Arnold WD, 549  
 Asofky R, 544  
 Atkinson JP, 461  
 Atra E, 59  
 Attias M, 383, 719  
 Atwater EC, 102  
 Avioli LV, 552

### B

Babcock J, 557  
 Bacon PA, 533  
 Bagby GC Jr, 665  
 Bagby MK, 163  
 Baker J, 397  
 Baker M, 120, 507  
 Ballas M, 251  
 Baragar FD, 558  
 Bardana EJ, 552  
 Barnett E, 563  
 Barnett EV, 537

Barr JH Jr, 525  
 Barry DW, 550  
 Baum J, 139, 278  
 Baumgartner WA, 534  
 Beasley RP, 737, 743  
 Beck F, 577  
 Becker KE, 550  
 Bell DA, 114  
 Benedek TG, 578  
 Bennahum DA, 534  
 Bennett PH, 114, 743  
 Bennett RM, 186, 298  
 Benson MD, 115, 535  
 Bentwich ZH, 138  
 Bernstein B, 535  
 Bertino JR, 79  
 Bias WB, 546  
 Billings S, 148  
 Binette JP, 536  
 Blau SP, 428, 777  
 Bluestone R, 241, 533, 537, 568, 576  
 Boisseau VC, 552  
 Bole GG Jr, 137, 231  
 Bovy RA, 557  
 Brand A, 576  
 Brandt K, 115, 116, 547  
 Brandt KD, 487, 535  
 Bress NM, 541  
 Britton MC, 629  
 Broder I, 225  
 Brown JC, 560  
 Brunner CM, 120  
 Bujek JS, 715  
 Burch F, 491  
 Burkhalter E, 428  
 Burstein AH, 397

### C

Calabro JJ, 117, 282, 536, 573  
 Caldwell JR, 537  
 Calkins E, 536  
 Champion DS, 537

Cannon PJ, 556  
 Cannon RB, 393  
 Carlson RP, 575  
 Carr RI, 552  
 Carroll PE, Jr, 557  
 Casarella W, 556  
 Case D, 556  
 Cassidy JT, 574  
 Cathcart E, 547  
 Cathcart ES, 115, 535, 566, 567  
 Caughey DE, 695  
 Chase G, 134  
 Cheatum DE, 545, 670  
 China G, 564  
 Christian CL, 548, 555, 568  
 Chu EW, 461  
 Chused TM, 561  
 Claypool R, 574  
 Clemente E, 122  
 Clements P, 537  
 Cohen A, 115, 547  
 Cohen AS, 115, 116, 324, 487, 535  
 Cole BC, 191  
 Coleman M, 548  
 Convery FR, 117  
 Cooke TDV, 538  
 Cooperating Clinics Committee of the American Rheumatism Association, 353  
 Coplon NS, 117  
 Cousar JB, 539  
 Cox MB, 540  
 Cracchiolo A III, 533  
 Cunningham JE, 576  
 Curtis JE, 34

## D

Dale DC, 657  
 D'Ambrosia RD, 539  
 Daniels T, 574  
 Davis GL, Jr, 52  
 Davis JS IV, 52, 120  
 Davis W, 397  
 Decker JL, 89, 120, 313, 345, 446, 461, 507, 533, 572, 715, 765, 776  
 Denardo G, 539  
 Dennis MV, 287  
 Deshmukh K, 560  
 Diamond H, 546  
 Diamond HS, 131, 539  
 Dilley J, 554  
 Dismuke SE, 118

Doneson IN, 499  
 Dorwart BB, 540, 543  
 Douglas SD, 241  
 Dubois EL, 540, 560  
 Dwyer JM, 455

## E

Eddie-Quarley AC, 186  
 Edgington TS, 578  
 Ehrlich GE, 259  
 Eisenbeis CH Jr, 525  
 Ellefson RD, 759  
 Engleman EP, 21, 30, 569  
 Epstein WV, 43  
 Erbe RW, 555  
 Esterly J, 134  
 Estes D, 59  
 Evans AS, 526

## F

Fauci AS, 657  
 Ferguson JL, 139  
 Finerman GAM, 533  
 Ford DK, 341  
 Fotino M, 137  
 Fox IH, 545  
 Fraga A, 541  
 Franck WA, 541  
 Frank MM, 120, 507  
 Frankel VH, 397  
 Franklin EC, 123, 565, 576  
 Frantz MM, 313  
 Frayha RA, 542  
 Fries JF, 117, 154, 542, 629  
 Friou GJ, 555, 560, 564  
 Frizzell J, 126  
 Frost HM, 272

## G

Gall EP, 543  
 Garcia-Kutzbach A, 118, 543  
 Garg SL, 117, 536  
 Gatter RA, 544  
 Gelfand MC, 118, 544

George S, 575  
 Gerber DA, 126  
 Gershon SL, 545  
 Gerwin RD, 120, 507  
 Gilbert RJ, 30  
 Gilliam JN, 545  
 Ginsberg B, 199  
 Ginzler E, 546  
 Girard DE, 665  
 Giuliano V, 554  
 Giuliano VJ, 119  
 Gocke DJ, 568  
 Goldberg L, 562  
 Goldberg LS, 241, 533, 576  
 Goldberg MA, 546  
 Goldenberg DL, 487, 547  
 Goldman M, 539  
 Gordon DA, 225, 305, 411  
 Gottlieb NL, 131  
 Gough WW, 548  
 Graham DR, 272  
 Granda JJ, 549  
 Grayzel AI, 419  
 Green FA, 549  
 Greenspan J, 574  
 Greenwald RA, 549  
 Grimley PM, 313, 550  
 Grossman A, 553  
 Gruber CM Jr, 635  
 Gupta N, 550  
 Gupta RC, 363  
 Gutman AB, 431  
 Guttman GG, 259

## H

Haakenstad AO, 551  
 Hadler NM, 507, 541  
 Hahn B, 561  
 Hahn BH, 120, 163, 552  
 Hahn TJ, 552  
 Halder NM, 120  
 Hamilton TR, 120, 163  
 Hansell JR, 540  
 Hanson V, 535  
 Hara M, 688  
 Harbeck RJ, 552  
 Harris ED Jr, 126, 552, 573  
 Harris ER, 553  
 Harrison WE Jr, 553  
 Harvey JP Jr, 562

Hassar M, 556  
 Hawker CD, 590  
 Healy LA, 426, 570, 737, 775  
 Henrard J, 114  
 Henson PM, 208  
 Herman JH, 287  
 Hersh EM, 34  
 Hess E, 569  
 Hess EV, 217  
 Hilgartner MW, 549  
 Hill VA, 534  
 Hirshaut Y, 97, 126, 701  
 Hoffman AA, 552  
 Hoffstein S, 132, 138, 606  
 Holborow EJ, 130  
 Holland PV, 406  
 Hollander JL, 771  
 Hollister JR, 10  
 Holman H, 542, 569  
 Holman HR, 154, 554  
 Holt PJJ, 136, 186, 298  
 Homma M, 688  
 Hopper K, 114  
 Hopps HE, 446  
 Horwitz DA, 120, 539  
 Howell DS, 129, 171, 179  
 Huffer WE, 363  
 Hunter D, 554  
 Hurd E, 139  
 Hurd ER, 84, 119, 545, 554, 670  
 Hurwitz D, 555

## I

Ignarro LJ, 560  
 Irvin W, 569  
 Irvin WS, 566  
 Ishikawa H, 121

## J

Jackson J, 122  
 Jacox R, 135  
 Jacox RF, 102, 278  
 James PG, 21  
 Jasin HE, 119, 122, 133  
 Johnson CC, 113  
 Johnson GJ, 130

Johnson JS, 1, 578  
Jurist JM, 66

## K

Kagen LJ, 555  
Kaplan D, 131, 546  
Kaplan MH, 122  
Kaplan SR, 123  
Kazmar R, 575  
Keiser H, 199, 468  
Kelley WN, 127  
Khairi MRA, 113  
Kimball AC, 555  
Kimball HR, 345  
Klinenberg JR, 537  
Kobayashi I, 471  
Koga T, 563  
Kotani S, 563  
Kourounakis L, 71  
Kraj MA, 578  
Krane SM, 555  
Krey PR, 324  
Krugmire RB Jr, 117  
Ku LC, 564  
Kunkel HG, 137, 138  
Lupusta MA, 71

## L

Leeb JE, 534  
Leonard DR, 552  
LeRoy EC, 270, 556, 559, 619  
Levin M, 123  
Levine L, 129  
Levy J, 537, 562  
Levy RM, 556  
Lewis D, 139  
Lewis SM, 298  
Liang GC, 10, 557  
Lidsky MD, 34, 148  
Lies RB, 369, 597  
Lightfoot RW Jr, 548, 549  
Lim W, 126  
Linke R, 123  
Little HA, 305  
Littleton C, 125  
Litwin A, 217  
Lockshin MD, 499, 568  
Lorber A, 534, 557  
Louria DB, 276  
Lynch JA, 124

## M

Machleder HI, 562  
Mackay IR, 455  
Mackenzie MR, 558  
Malawista SE, 749  
Man SC, 558  
Mandell B, 571  
Mannik M, 10, 551  
Marchesano JM, 536  
Marcus RE, 646  
Margolis HM, 525, 578  
Maricq HR, 619  
Martens M, 397  
Martin JR, 553  
Martinez VA, 127, 705  
Masi AT, 118, 543, 567  
Mattioli M, 124  
May C, 569  
Mayor M, 397  
McCarty DJ, 132, 570  
McCluskey RT, 549  
McDevitt HO, 154  
McDuffie F, 569  
McIntosh RM, 563  
McManus J, 217  
McWhorter JE, 559  
Medsger TA Jr, 578  
Meilman E, 577  
Messner RP, 369, 534, 597  
Meyer HM Jr, 446  
Meyer KF, 21, 30  
Michelitch JH, 313  
Mikkelsen WM, 359  
Miller EJ, 128  
Miller ML, 491  
Millman I, 543  
Mintz G, 541  
Miyawaki S, 726  
Montoye HJ, 359  
Moore A, 137  
Morris A, 134  
Morris AD, 125  
Moskowitz RW, 397  
Mueller MN, 66  
Muniz OE, 171

## N

Nagle R, 544  
Nankin HR, 135  
Narita T, 563  
Nastro L, 562  
Natali PG, 579

Natvig JB, 573  
Nelson RA Jr, 71  
Nies KM, 560  
Nimni ME, 560

## O

Ogryzlo MA, 411  
Oronsky AL, 560, 564  
Orozco J, 541  
Osterland CK, 120, 163, 561

## P

Pan SF, 135  
Parker L, 561  
Parker LM, 561  
Parkman P, 126  
Parrino GR, 536  
Patzakis MJ, 562  
Paulus HE, 550, 562  
Pearce D, 537  
Pearson CM, 241, 533, 550, 562, 563, 568  
Peltier A, 59  
Penso JS, 563  
Peppercorn M, 406  
Perper RJ, 560, 564  
Persellin RH, 564  
Person DA, 125, 677  
Peter JB, 562  
Petty RE, 574  
Phelps F, 590  
Phillips P, 126  
Phillips PE, 97, 701  
Pillarisetty R, 573  
Pinals RS, 126  
Pinnell SR, 555  
Pita JC, 171, 179  
Pless IB, 278  
Plotz PH, 345, 406  
Pollock BH, 525  
Popovtzer MM, 363  
Postlethwaite AE, 127  
Powell M, 574  
Powers TR, 569  
Pras M, 123  
Pruzanski W, 411

## Q

Quismorio FP, 560, 564  
Quismorio FP Jr, 555

## R

Ramsdell CM, 127  
Ransom JC, 122  
Rawls WE, 125, 677  
Reginato AJ, 127, 705  
Reichlin M, 124  
Retailliau H, 737  
Rich RR, 1  
Richardson JA, 265  
Richer SM, 538  
Richmond JD, 544  
Ricketts H, 702  
Ridolfo AS, 635  
Riggins RS, 539  
Ritchie RF, 726  
Roberts SP, 120  
Robertson PB, 128  
Robin JA, 128  
Robinson DR, 129, 541  
Rodda BE, 635  
Rodman GP, 268  
Rodnan GP, 128, 135  
Rogers B, 577  
Rosenthal CJ, 565  
Rosenthal M, 572  
Roth H, 446  
Rowley MJ, 455  
Rubin A, 635  
Ryan WE, 759

## S

Salisbury KW, 406  
Samaha RJ, 566  
Sammarco J, 397  
Sanda M, 564  
Sapolsky AI, 129  
Scarola JA, 542  
Schachter J, 21, 30  
Schaff Z, 550  
Schaller J, 130  
Scheinberg MA, 566, 567  
Scherer AT, 567  
Schlosstein L, 568  
Schmid FR, 393, 569  
Schnapp JJ, 499  
Scholar EM, 123  
Schultz DR, 131  
Schumacher HR, 127, 540, 543, 705  
Schur PH, 122, 544  
Schwartz CE, 549  
Senter RG, 120

Sergeant JS, 568  
 Sharon E, 131, 539, 546  
 Sharp G, 134, 569  
 Sharp GC, 125, 154  
 Sharp JT, 34, 125, 148, 677  
 Shen AC, 569  
 Sherman RL, 548  
 Shoop JD, 534  
 Shulman LE, 542, 546  
 Siegal FP, 138  
 Siegel RC, 117  
 Silcox DC, 132, 570  
 Simkin PA, 557, 570, 702  
 Simsarian JP, 446  
 Simson J, 526  
 Skeith MD, 570  
 Skinner M, 115, 116  
 Sledge CB, 376  
 Sliwinski AJ, 132, 388  
 Smiley JD, 341  
 Smiley WK, 130  
 Smith CB, 191  
 Smith DE, 21  
 Smith FG, Jr, 563  
 Smith H, 129  
 Smyth C.J, 363  
 Smythe HA, 411  
 Soberman RJ, 132  
 Spilberg I, 133, 571  
 Stastny P, 121, 572  
 Steinberg AD, 92, 118, 406, 533, 544, 561, 572  
 Stevens JG, 533  
 Steward MW, 573  
 Stillman JS, 106, 122  
 Stobo JD, 118  
 Stolzer BL, 525  
 Strandness DE, Jr, 117  
 Strosberg JM, 573  
 Strunk SW, 670  
 Sugai S, 573  
 Sullivan DB, 574  
 Sumner DS, 702  
 Sylvester R, 574  
 Sylvester RA, 383, 719

## T

Tabbara K, 574  
 Takahashi M, 535  
 Talal N, 345, 383, 422, 573, 574, 719  
 Tan EM, 579  
 Tan M, 43  
 Tateishi H, 133

Taylor H, 134  
 Taylor J, 134  
 Terasaki P, 568  
 Terasaki PI, 560  
 Tesar J, 575  
 Thoburn R, 137  
 Thompson J, 562  
 Tolchin S, 128  
 Tolchin SF, 135  
 Trieshmann H, 135  
 Tse RL, 136  
 Tuffanelli DL, 383  
 Turner MW, 573

## V

Van Arman CG, 575  
 Vance SE, 564  
 Vaughan JH, 114, 578  
 Versey J, 136  
 Virshup AM, 388

## W

Wakem CJ, 695  
 Walker SE, 137, 231  
 Walsh JR, 665  
 Ward JR, 191, 491  
 Ward LE, 759  
 Warrick P, 635  
 Waxman BA, 376  
 Waxman J, 491  
 Webb FW, 241  
 Weiner JM, 540  
 Weisbart R, 576  
 Weisman MH, 576  
 Weissmann G, 132, 138, 576, 606  
 Wernet P, 137  
 Weyl S, 542  
 Whitaker JN, 120, 507  
 Whitehouse M, 577  
 Whitehouse MJ, 569  
 Wiener S, 577  
 Wierchowicki M, 540  
 Wilkes RM, 446  
 Williams ED, 298  
 Williams RC, Jr, 369, 597  
 Willkens RF, 743  
 Wiltse DW, 287

Winchester R.J. 138  
Winkelstein A. 135  
Woessner F.J. 129  
Wolff SM, 345, 461, 657, 715  
Wright DG, 749

## Y

Yamasaki K, 688

Young RC, 569  
Yu D, 577

## Z

Zawadzki Z.A. 578  
Zeiders RS, 578  
Ziff M, 119, 121, 122, 133, 139, 471, 545, 554, 572, 670  
Zimmer H, 217  
Zurler RB, 138, 251, 606  
Zvaifler N.J. 576





## Subject Index

(Page numbers in *italics* refer to abstracts)

### A

- Acromegaly, plasma PPI in, 132
- Acupuncture, in rheumatoid arthritis, 569
  - with painful knees, 558
- Addiction to drugs, and intervertebral disc space infections, 562
- Adenosine monophosphate, cyclic, effects on crystal-induced synovitis, 136
- Adjuvant arthritis
  - from bacterial cell walls, 563
  - cobra venom factor affecting complement in, 71
  - gold therapy in, affecting mitochondrial function, 534
  - prostaglandin E<sub>1</sub> in, 251
  - and suppression of inflammation in adrenalectomized rats by prostaglandins, 606
- Adrenalectomized rats, suppression of inflammation in, by prostaglandins, 606
- Age of onset, in juvenile RA, 574
- Aging NZB/NZW mice, cellular immunity in, 118
- Agitation, mechanical, effects in crystal-induced arthritis, 540
- Alaskan Eskimos, rheumatoid arthritis in, 737
- Albumin, serum, sodium rate binding to, 537
- Allopurinol, single daily dose in gouty hyperuricemia, 128
- American Rheumatism Association, presidential addresses, 106, 765
- Amyloid fibrils
  - nonimmunoglobulin component of, 123
  - proteins in
    - antigenicity of, 115
    - homology with Bence-Jones protein, 116
- Amyloidosis
  - lymphocyte and macrophage function in, 567
  - neuropathy in, 535
  - and P-component in plasma, 536
  - and Reiter's disease, fatal case of, 695
- Anaphylaxis, and antigen deposition, parasympathetic blockade affecting, 556
- Antibiotics, in experimental bedsonial arthritis, 30
- Antibody formation. *See* Immunology
- Arteritis, giant cell, diagnosis of, 702
- Arthritis
  - acute infectious, 118
    - from gram-negative bacilli, staphylococci and streptococci, 547
  - adjuvant-induced. *See* Adjuvant arthritis
  - bacterial, in adults, 543
  - bedsonial, experimental, 21, 30

- crystal-induced. *See* Crystal-induced disease
- destructive polyarthritis with *Mycobacterium kansasii* infection, 665
- gonococcal, 115
- hemophilic, 549
- from Herpes simplex virus, 241, 533
- osteoarthritis. *See* Osteoarthritis
- psoriatic
  - in children, 117, 278
  - 6-mercaptopurine in, 139
- rheumatoid. *See* Rheumatoid arthritis
- from 6-sulfanilamidoindazole, and induction of Schwartzman reaction, 491
- Arthroplasties, replacement, for knee, 124, 532, 533
- Aspirin. *See* Salicylates
- Australia antigen
  - and polyarteritis nodosa, 568
  - and synovial membrane in hepatitis, 543
- Autoimmune disease in NZB/NZW mice
  - comparison of drugs in, 120, 163
  - cyclophosphamide in, 134
  - estrogens affecting, 231
  - and tolerance to DNA, 561
- Azathioprine
  - chemical action and pharmacology of, 79
  - complications from, 533
  - glomerular deposits after, in NZB/NZW mice, 544
  - and immune response to flagellin, 455
  - immunosuppressive and antiinflammatory properties of, 84
  - in lupus erythematosus, 546
  - in lupus nephritis, 572
  - in NZB/NZW nephritis, 120, 163
  - in rheumatoid arthritis, double-blind crossover study of, 411, 776
  - withdrawal of, in SLE, 131

### B

- Bacterial arthritis, in adults, 543
- Bacterial cell walls, inducing polyarthritis, 563
- Bedsonial arthritis, experimental, 21
  - antibiotic therapy in, 30
- Bence-Jones protein, and glycosaminoglycans in amyloid fibrils, 116
- Bladder toxicity, from cyclophosphamide, 461

## Bone

status in rheumatoid arthritis, 66

steroid-induced loss in RA, 552

Bone marrow, granulocyte reserves in rheumatic disease, 345

## Book reviews

Acupuncture Therapy: Current Chinese Practice (*Leong et al.*), 779

Arthritis and Allied Conditions: A Textbook of Rheumatology (*Hollander et al., eds.*), 528

Beyond the Copper Bracelet: What You Should Know About Arthritis (*Healy, Wilske & Hansen*), 284

The Hand Book (*Johnson*), 703

Immunology, Immunopathology and Immunity (*Sell*), 284

The Radiology of Joint Disease (*Forrester & Nesson*), 779

The Truth About Arthritis Care (*Calabro & Wykert*), 703

Bowel symptoms, in spondylitis, 549

Brain scans, in lupus cerebritis, 534

## C

Calcific periarthritis, in twins, 393

Calcinosis, in scleroderma, 542

Calcium pyrophosphate crystals

deposition in ochronotic arthropathy, 705

inflammation induced by, 133

*Candida guilliermondii* infection of knee, in RA, 272

Capillary abnormalities in fingers, in connective tissue disease, 619

Carcinoma of pancreas, with polyarthritis and subcutaneous nodules, 388

## Cartilage

antigenic components in RA, 287

collagen fibrils affected by rheumatoid synovial collagenase, 552

collagen susceptibility to collagenases, 128

degradation by protease from leukocytes, 560

in familial chondrocalcinosis, 127

in ferritin-induced arthritis, 133

localization of antigen to cartilage tissues, 538

lysozyme interaction with proteoglycans, 549

neutral enzyme activity in, 129

normal and osteoarthritic, collagen metabolism in, 560

osteoarthritic, proteoglycan degradation in, 179

Cathepsin D activity, in articular cartilage, 129

Cell-mediated immune response, in SLE, 688

Cellular immunity, in rheumatoid arthritis, 499

Cerebritis, lupus, brain scans in, 534

## Cerebrospinal fluid

DNA antibodies in, in SLE, 552

fourth component of complement in, in SLE, 120, 507

## Chemotaxis

inhibition by complement depletion with cobra factor, 577

*in vivo* quantitation of, 564

urate crystal-induced, 571

## Chondrocalcinosis, articular, 171

familial, cartilage in, 127

with iron overload, 305

See also Pseudogout

Chondrocytes, low oxygen concentration affecting, 646

Chromosomes, cyclophosphamide affecting, 135

Clq-mediated precipitation of immune complexes, 558

## Cobra venom factor

affecting complement in adjuvant-induced disease, 71

complement depletion by, and chemotaxis inhibition, 577

## Colchicine

affecting prostaglandin synthesis by synovial cultures, 129

and enzyme release from leukocytes in phagocytosis, 749

Cold, effects in crystal-induced arthritis, 540

Colitis, ulcerative, and spondylitis, 549

## Collagen

cartilage, susceptibility to collagenases, 128

hydroxylase in fibroblasts, and hydroxylysine deficiency, 555

metabolism in normal and osteoarthritic cartilage, 560

Collagenase, rheumatoid synovial, affecting cartilage collagen fibrils, 552

Collagenous tissues of joints, trapping of immune complexes in, 122

## Complement

activation of alternate pathway by cryoglobulins, 575

cobra venom factor affecting, in adjuvant-induced disease, 71

depletion by cobra factor, and chemotaxis inhibition, 577

efficient fixation by 7SIgM, 537

fourth component in cerebrospinal fluid in SLE, 120, 507

gold affecting functional activities of components, 131

metabolism in RA, 136

Connective tissue disorders. See Rheumatic and connective tissue diseases

## Corticosteroids

bone loss from, in RA, 552

and cell-mediated immunity in SLE, 565

cortisol affecting enzyme release from leukocytes in phagocytosis, 749

and enzyme release from leukocyte lysosomes, 564

and lupus nephritis in children, 563

Counterimmunoelectrophoresis, for detection of circulating DNA, 52

Cricoarytenoid joint, in rheumatoid arthritis, 553

## Cryoglobulinemia

in infectious endocarditis, 555

monoclonal IgG, vasculitis with, 548

Cryoglobulins, and activation of alternate pathway of complement, 575

#### Crystal-induced disease

from calcium pyrophosphate crystals, 133  
and effects of heat, cold, and mechanical agitation, 540  
*See also* Urate crystals

#### Cyclophosphamide

affecting lymphocytes in connective tissue diseases, 554  
autoantibody response to, and lymphoma development in mice, 137

bladder toxicity from, 461

chemical action and pharmacology of, 79

chromosome abnormalities from, 135

complications from, 533

dosage in connective tissue diseases, 120

glomerular deposits from, in NZB/NZW mice, 544

and immune response to flagellin, 455

immunosuppressive and antiinflammatory properties of, 84

in lupus erythematosus, 154

in lupus nephritis, 572

in NZB/NZW nephritis, 120, 134

lymphocyte deactivation of metabolites of, 577

in polymyositis, 154

in rheumatoid arthritis, 148

immune response to, 34

and tolerance to DNA in NZB/NZW mice, 561

and tumor development, 524

in Wegener's granulomatosis, 657

Cysts, antecubital, in RA, valvular mechanisms in, 259

Cytochalasin B, and lysosomal enzyme release from leukocytes, 138

Cytotoxic drugs, in rheumatic diseases, 92

## D

Death in SLE, causes of, 540

Degenerative joint lesions, after partial meniscectomy, 397

#### Dermatomyositis

finger capillary abnormalities in, 619

muscle ischemia in, 567

Disodium etidronate, in Paget's disease, 113

#### DNA

antibodies to, in SLE, 114, 199, 554

circulating, detection with counterimmunoelectrophoresis, 52

extractable nuclear antigen affecting anti-DNA reaction, 125

#### native

antibodies to, in SLE sera, 199

cellular response to, in macrophage inhibitory test, 688

labeled with iodine-125, in radioimmunoassay, 468

strandedness of, and reactivity with sera, 566

tolerance to, in autoimmune disease of NZB/NZW mice, 561

#### Drainage

surgical, in acute infectious arthritis, versus medical treatment, 547

of thoracic duct lymphocytes, in RA, 562

Drug addiction, and intervertebral disc space infections, 562

Drug studies, organization of, 428

## E

Elbow, antecubital cysts in RA, valvular mechanisms in, 259

Endocarditis, infectious, cryoglobulinemia in, 555

Endotoxin, adsorbed in urate crystals, and gout induction, 575

#### Enzymes

activity in articular cartilage, 129

#### lysosomal

corticosteroids affecting release of, 564

release from leukocytes, agents affecting, 138, 749

release by monosodium urate, 132

release from neutrophils in phagocytosis, 208

synovial acid phosphatase in rheumatoid diseases, 376

Epstein-Barr virus antibody, in SLE, 97

Eskimos, Alaskan, rheumatoid arthritis in, 737

Estrogens, affecting autoimmune disease in NZB/NZW mice, 231

## F

#### Familial conditions

calcific periartthritis in twins, 393

SLE in male siblings, 221

Febrile juvenile RA, acute, 536

Felty's syndrome, marrow granulocyte reserves in, 345

Femoral head circulation, scanning studies of, 539

Fender-kicker syndrome, 102

#### Fenoprofen

interactions with aspirin, 635

in rheumatoid arthritis, 629

Ferritin-induced arthritis, electron microscopy of, 133

Fertility, and lupus erythematosus, 541

Fetal wastage, and lupus erythematosus, 541

#### Fibrils

amyloid. *See* Amyloid fibrils

of cartilage collagen, affected by rheumatoid synovial collagenase, 552

Finger capillary abnormalities, in connective tissue disease, 619

Flagellin, immune response to, drugs affecting, 455  
Foot, fender-kicker syndrome of, 102  
Fractures, metatarsal, in fender-kicker syndrome, 102

## G

Generic equivalents, 775  
Genetic control of salicylate metabolism, 550  
Genetic studies, in ankylosing spondylitis, 573  
Geometric knee prosthesis, 532, 533  
Giant cell arteritis, diagnosis of, 702  
Glomerular deposits, after drug therapy of NZB/NZW mice, 544  
Glycopyrrolate, affecting uric acid levels, 127  
Glycosaminoglycans, in amyloid fibrils, homology with Bence-Jones protein, 116  
Gold therapy  
  and functional activities of complement components, 131  
  and metabolism of gold in lactation, 777  
  and mitochondrial function in adjuvant arthritis, 534  
  in rheumatoid arthritis, 353  
  weekly injections in, 557  
Gonococcal arthritis, 115  
Gout  
  induced with urate with adsorbed endotoxin, 575  
  polyarticular, 541  
  progress in knowledge of, 431  
Gouty hyperuricemia, single daily dose of allopurinol in, 128  
Gram-negative bacilli, acute infectious arthritis from, 547  
Granule enzymes. *See* Enzymes, lysosomal  
Granulocyte reserves in marrow, in rheumatic diseases, 345  
Granulomatosis, Wegener's, cyclophosphamide in, 657  
Gutman, Alexander, 522

## H

Hageman factor, and urate crystal-induced arthritis, 571  
Heart  
  infectious endocarditis, cryoglobulinemia in, 555  
  pathogenesis of rheumatic valvular disease, 122  
  pericardial disease in scleroderma, 559  
  studies in juvenile RA, 535  
Heat, effects in crystal-induced arthritis, 540  
Hemochromatosis, arthropathy of, 305  
Hemodialysis and transplantation  
  in lupus nephritis, 117  
  for renal failure in scleroderma, 265  
Hemophiliac arthritis, 549  
Hepatitis  
  synovial membrane in, and Australia antigen, 543  
  with tuberculosis and SLE, 406

Hepatotoxicity of salicylates, in juvenile RA, 1  
Heroin addicts, intervertebral disc space infections in, 562  
Herpes simplex virus, arthritis from, 241, 533  
Hip replacement, and thromboembolic disease, 117  
Histidine, in rheumatoid arthritis, 126  
Histonase activity, in articular cartilage, 129  
HL-A antigens  
  in lupus erythematosus, 546  
  and lymphocytotoxic antibodies in SLE, 560  
  W27 specificity and ankylosing spondylitis, 568  
Hydralazine urinary metabolites, in SLE, 217  
Hydroxylysine deficient collagen, and collagen hydroxylase in fibroblasts, 555  
Hyperostosis of spine, in Pima Indians, 114

## I

Immune complexes, in synovial fluid, 10  
Immune response to cyclophosphamide, in RA, 34  
Immunofluorescence  
  of antigammaglobulin antibody, 59  
  of thymocytotoxic antibody, 561  
Immunoglobulins  
  abnormalities in RA, 578  
  deposits in skin in SLE, 564  
IgG  
  antigens interacting with low affinity rheumatoid factors, 573  
  in juvenile RA, 126  
IgM, and complement fixation, 537  
  molecular basis of interaction with biomembranes, 576  
  in temporal arteries, 557  
Immunology  
  antibodies to DNA in CSF, in SLE, 552  
  antibodies in DNA and RNA in SLE, 554  
  antibodies to extractable nuclear antigen, 125, 569  
  antibodies to reovirus RNA in SLE, 383, 719  
  antibody-like material in lupus erythematosus, 43  
  antibody titers in SLE, 526  
  anti-DNA antibody forming cells in SLE, 114  
  antigen dependency of migration inhibitory factor, 576  
  antigenicity of amyloid fibril proteins, 115  
  antinuclear antibodies  
    in iridocyclitis and JRA, 130  
    in NZB/NZW mice, after estrogen, 231  
  antinucleolar antibody, in rheumatic diseases, 726  
  assay for antibodies to nDNA in SLE sera, 199  
  Australia antigen  
    and polyarteritis nodosa, 568  
    and synovial membrane in hepatitis, 543  
  autoantibody response in NZB/NZW mice after cyclophosphamide, 137  
  blockage of lymphocyte surface antigens in SLE, 137  
  cartilage antigenic components in RA, 287

cell-mediated immune response in SLE, 688  
 after steroid therapy, 565  
 cellular immunity  
   in aging NZB/NZW mice, 118  
   in rheumatoid arthritis, 499  
 changes in hemophilic arthritis, 549  
 Clq-mediated precipitation of immune complexes, 558  
 cultured B-immunocytes from rheumatoid synovium, 341  
 Epstein-Barr virus antibody in SLE, 97  
 HL-A antigens. *See* HL-A antigens  
 humoral antibody to flagellin, drugs affecting, 455  
 localization of antigen to cartilage tissues, 538  
 lymphocytotoxic antibody activity of sera in SLE, 369  
 monoclonal IgG cryoglobulinemia, with vasculitis, 548  
 nonimmunoglobulin component of amyloid fibrils, 123  
 parasympathetic blockade affecting anaphylaxis and antigen deposition, 556  
 pathogenesis of vasculitis in RA, 576  
   RNA protein antigen in SLE serum, 124  
   saturation of RES by immune complexes, 551  
   thymocytotoxic antibody of NZB mice, 561  
 trapping of immune complexes in joint collagenous tissues, 122  
 triclinal rheumatoid factor gammopathy, 135  
 virus antibody and IgG levels in juvenile RA, 126  
*See also* Autoimmune disease in NZB/NZW mice  
 Immunosuppressive drugs, in rheumatic diseases, 92  
 Immunosuppressive effects of B-lymphocytes in RA, 537  
 Indians  
   Pima, hyperostosis of spine in, 114  
   Yakima, rheumatoid arthritis in, 743  
 Infectious arthritis, 118, 191  
   from gram-negative bacilli, staphylococci, and streptococci, 547  
   medical treatment versus surgical drainage, 547  
 Intellectual achievement, and serum uric acid, 359  
 Intervertebral disc space infections, in heroin addicts, 562  
 Iodine-125, for labeling of native DNA, 468  
 Iridocyclitis, in juvenile RA, 130  
   antinuclear antibodies in, 130  
 Iron  
   overload with chondrocalcinosis, 305  
   synovial deposition in RA, 298  
 Iron-binding protein, in synovial fluid, 186  
 Ischemia, in polymyositis muscle, 567

## J

Joints  
 cartilage conditions. *See* Cartilage  
 degenerative lesions after partial meniscectomy, 397  
 polyarticular gout, 541  
 rheumatoid, lymphokines in, 572

trapping of immune complexes in collagenous tissues of, 122

## K

Kidney  
 comparison of three drugs in NZB/NZW nephritis, 120  
 hemodialysis and transplantation  
   in lupus nephritis, 117  
   in scleroderma, 265  
   in lupus erythematosus, 670  
   lupus nephritis in children, after steroid therapy, 563  
   in scleroderma, 556  
   suppression of uric acid secretion in renal hypouricemia, 570  
 Knee  
   *Candida* infection of, in RA, 272  
   degenerative lesions after partial meniscectomy, 397  
   osteoarthritis of, intraosseous venography in, 124  
   pain in RA, acupuncture affecting, 558  
   replacement of, 124  
   with geometric prosthesis, 532, 533  
   with polycentric prosthesis, 533

## L

Lactation, gold metabolism in, 777  
 Lactoferrin, in synovial fluid, 186  
 Leukocytes  
   enzyme release from  
     corticosteroids affecting, 564  
     cytochalasin B affecting, 138  
     in phagocytosis, agents affecting, 749  
   inhibition of mixed culture responses by sera from rheumatic disease patients, 597  
   protease from, cartilage degradation by, 560  
   in Wegener's granulomatosis, cyclophosphamide affecting, 657  
 Lipid synovial effusion in SLE, 759  
 Liver damage, from salicylates in juvenile RA, 1  
   *See also* Hepatitis  
 Lupus erythematosus  
   discoid, and antibodies to viral RNA, 383  
   systemic  
     and abnormal structures in lymphocytes, 313  
     and antibodies to DNA and RNA, 554  
     and antibodies to native DNA in sera, 199  
     and antibodies to reovirus RNA, 719  
     antibody-like material in, 43  
     antibody titers in, 526  
     anti-DNA antibody forming cells in, 114  
     azathioprine in, 546

and B and T cell lymphopenia, 566  
 blockage of lymphocyte surface antigens in, 737  
 causes of death in, 540  
 cell-mediated immune response in, 565, 688  
 cerebritis in, brain scan of, 534  
 complications from cytotoxic agents in, 533  
 cyclophosphamide in, 154  
 and DNA antibodies in CSF, 552  
 and effects of cyclophosphamide on lymphocytes, 554  
 Epstein-Barr virus antibody in, 97  
 experimental skin lesions resembling, 579  
 finger capillary abnormalities in, 619  
 fluorescent band test in, prognostic significance of, 545  
 and fourth component of complement in CSF, 120, 507  
 histocompatibility antigens in, 546, 560  
 hydralazine urinary metabolites in, 217  
 and immunoglobulin deposits in skin, 564  
 and inhibition of lymphocyte activation by sera, 539  
 and inhibition of mixed culture responses by sera, 597  
 kidney in, 670  
 and lipid synovial effusion, 759  
 lymphopenia in, 119  
 lymphocytotoxic antibodies in, 369, 560  
 in male siblings, 221  
 marrow granulocyte reserves in, 345  
 and pregnancy, 541  
 prognosis in, 542  
 and RNA protein antigen in sera, 124  
 unique presentation of, 428  
 with viral hepatitis and tuberculosis, 406  
 and withdrawal of azathioprine, 131

**Lupus-like tubular structure, in lymphoid cells, 550**

**Lupus nephritis**  
 in children, after steroid therapy, 563  
 cyclophosphamide or azathioprine in, 572  
 hemodialysis and transplantation in, 117

**Lymphocytes**  
 abnormal structures in SLE, 313  
 blockage of surface antigens in SLE, 737  
 culture of B-immunocytes from rheumatoid synovium, 341  
 cyclophosphamide affecting, in connective tissue diseases, 554  
 deactivating cyclophosphamide metabolites, 577  
 function in amyloidosis, 567  
 heterogeneity and function of, 422  
 immunosuppressive effects of B cells in RA, 537  
 inhibition of activation by SLE sera, 539  
 nucleic acid enzyme levels in, in RA, 123  
 proportion of B and T cells in RA joint fluids, 138  
 in synovial fluid, in early RA, 544  
 T cells in rheumatic diseases, 578  
 thoracic duct, drainage in RA, 562

**Lymphocytotoxic antibodies**  
 activity of sera in SLE, 369  
 and HLA-A antigens in SLE, 560

**Lymphoid cells**  
 lupus-type tubular structures in, 550  
 in rheumatoid synovium, 471

**Lymphokines**  
 inducing synovitis, 121  
 in rheumatoid joints, 572

**Lymphoma**  
 and monoclonal macroglobulins in NZB/NZW mice, 573  
 in NZB/NZW mice, after cyclophosphamide, 137

**Lymphopenia, in lupus erythematosus, 119, 566**

**Lysosomes, enzyme release from. See Enzymes, lysosomal**

**Lysozyme, cartilage, interaction with proteoglycans, 549**

## M

**M-components in serum, and amyloidosis with neuropathy, 535**

**Macroglobulins, monoclonal, and lymphoma in NZB/NZW mice, 573**

**Macrophage**  
 function in amyloidosis, 567  
 inhibitory test, and cellular response to native DNA, 688

**Menisectomy, partial, inducing degenerative lesions, 397**

**6-Mercaptopurine, in psoriatic arthritis, 139**

**Metatarsal fractures, in fender-kicker syndrome, 102**

**Methotrexate**  
 chemical action and pharmacology of, 79  
 immunosuppressive and antiinflammatory properties of, 84

**Mexican medicine, comments on, 426, 776**

**Migration inhibitory factor, antigen dependency of, 576**

**Mitochondrial function, gold therapy affecting, in adjuvant arthritis, 534**

**Muscle ischemia, in polymyositis, 567**

**Mycobacterium kansasii infection, and destructive polyarthritis, 665**

**Mycoplasmas**  
 in connective tissue diseases, 125, 677  
 in rheumatoid tissue, 191

## N

**Nephritis**  
 lupus. *See* Lupus nephritis  
 in mice. *See* Autoimmune disease of NZB/NZW mice

**Neuropathy, in amyloidosis, 535**

**Neutrophils, release of granule enzymes from, in phagocytosis, 208**

**Nicotinic acid, affecting uric acid metabolism, 545**

**Nodules, subcutaneous, with polyarthritis and carcinoma of pancreas, 388**

Nuclear antigen, extractable, antibodies to, 125, 569  
Nucleic acids, enzyme levels in lymphocytes in RA, 123  
Nucleolus, antibody to, in rheumatic diseases, 726

## O

Ochronotic arthropathy, with calcium pyrophosphate crystal deposition, 705  
Osteitis deformans, disodium etidronate in, 113  
Osteoarthritis  
  and acid phosphatase in synovium, 376  
  and collagen metabolism in cartilage, 560  
  and degradation of proteoglycans in cartilage, 179  
  of knee, intraosseous venography of, 124  
  plasma PPI in, 132  
  and synovial fluid inorganic phosphate levels, 570  
Osteoporosis, regional migratory, 363  
Oxygen, low concentration of, affecting chondrocyte cultures, 646

## P

P-component in plasma, purification of, 536  
Paget's disease, disodium etidronate in, 113  
Pancreas, carcinoma of, with polyarthritis and subcutaneous nodules, 388  
Parasympathetic blockade, and anaphylaxis and antigen deposition in rat, 556  
Parathyroid hormone levels, in pseudogout, 590  
Peptide, rheumatoid factor-reactive, 134  
Periarthritis, calcific, in twins, 393  
Pericardial disease, in scleroderma, 559  
Phagocytosis  
  and enzyme release from leukocytes, agents affecting, 749  
  inhibiting factor in RA serum, 132  
  and release of granule enzymes from neutrophils, 208  
Phalangeal fractures of foot, in fender-kicker syndrome, 102  
Phosphate, inorganic, synovial fluid levels in pseudogout and osteoarthritis, 570  
Polyarthritis nodosa, and Australia antigen, 568  
Polyarthritis  
  destructive, with *Mycobacterium kansasii* infection, 665  
  induction with bacterial cell walls, 563  
  with subcutaneous nodules and carcinoma of pancreas, 388  
Polyarticular gout, 541  
Polymyositis  
  cyclophosphamide in, 154  
  and toxoplasmosis, 555  
Prednisolone, in NZB/NZW nephritis, 120, 163  
Pregnancy, and lupus erythematosus, 541  
Prognosis in SLE, 542

Prostaglandins  
  PGE<sub>1</sub> in adjuvant arthritis, 251  
  and suppression of inflammation in adrenalectomized rats, 606  
  synthesis by synovial cultures, colchicine affecting, 129  
Prostheses, for knee, 532, 533  
Protease  
  activity in articular cartilage, 129  
  from leukocytes, cartilage degradation by, 560  
Protein  
  in amyloid fibrils. *See* Amyloid fibrils  
  iron binding, in synovial fluid, 186  
Proteoglycans  
  cartilage lysozyme interaction with, 549  
  degradation in osteoarthritic cartilage, 179  
Pseudogout, 171  
  parathyroid hormone levels in, 590  
  plasma PPI in, 132  
  and synovial fluid inorganic phosphate levels, 570  
Psoriatic arthritis  
  in children, 117, 278  
  6-mercaptopurine in, 139  
Pyogenic infection, and bacterial arthritis, 543  
Pyrazinamide suppression test, 539  
Pyrophosphate, inorganic, in biologic fluids, 132  
  in pseudogout, 171

## R

Radioimmunoassay  
  for antibodies to reovirus RNA in SLE, 719  
  and labeling of native DNA with iodine-125, 468  
Reiter's syndrome  
  and amyloidosis, fatal case of, 695  
  and experimental bedsonia arthritis, 21, 30  
Reovirus RNA, antibodies to, in SLE, 383, 719  
Reserpine, intraarterial, 526  
Reticuloendothelial system, saturation by immune complexes, 551  
Rheumatic and connective tissue diseases  
  antinuclear antibody in, 726  
  cyclophosphamide dosage in, 120  
  finger capillary abnormalities in, 619  
  T lymphocytes in, 578  
  valvular, pathogenesis of, 122  
  viruses and mycoplasma in, 125, 677  
Rheumatoid arthritis  
  and acid phosphatase in synovium, 376  
  acupuncture in, 569  
  for knee pain, 558  
  in Alaskan Eskimos, 737  
  azathioprine in, double-blind crossover study of, 411, 776  
  and *Candida* infection of knee, 272  
  cartilage antigenic components in, 287

cellular immunity in, 499  
 complement metabolism in, 136  
 complications from cytotoxic agents in, 533  
 cricoarytenoid joint in, 553  
 and culture of B-immunocytes from synovium, 341  
 cyclophosphamide in, 148  
   immune response to, 34  
 dysimmunoglobulinemias in, 578  
 early, synovial fluid lymphocytes in, 544  
 and effects of cyclophosphamide on lymphocytes, 554  
 fenoprofen calcium in, 629  
 finger capillary abnormalities in, 619  
   gold salt therapy in, 353  
   histidine in, 126  
 immunosuppressive effects of B-lymphocytes in, 537  
 infectious etiology of, 191  
   and inhibition of mixed culture responses *in vitro*, 597  
 juvenile  
   acute febrile, 536  
   adult onset of, 715  
   ages of onset in, 574  
   iridocyclitis in, 130  
   salicylate hepatotoxicity in, 1  
   Sjogren's syndrome in, 122  
   studies of cardiac involvement, 535  
   virus antibody and IgG levels in, 126  
   and virus replication in cultured synovial cells, 114  
 and lymphoid cells in synovium, 471  
 and lymphokines in joints, 572  
 marrow granulocyte reserves in, 345  
 Mexicali treatment of, 426  
 and nucleic acid enzyme levels in lymphocytes, 123  
 and phagocytosis inhibiting factor in serum, 132  
 proportion of B and T lymphocytes in joint fluids, 138  
 and reconstruction of wrist, 553  
 skeletal status in, 66  
 steroid-induced bone loss in, 552  
 synovial iron deposition in, 298  
 thoracic duct lymphocyte drainage in, 562  
 and uridine incorporation into RNA of cultured cells, 419  
 vasculitis in, immunopathogenesis of, 576  
 virologic studies in, 446  
 in Yakima Indians, 743

Rheumatoid biologically active factor (RBAF), related to clinical status, 225

Rheumatoid factors  
   immunofluorescence for detection of, 59  
   low affinity, interaction with IgG antigens, 573  
   peptide reactive with, 134  
   triclinal gammopathy, 135

Rheumatoid synovial collagenase, affecting cartilage collagen fibrils, 552

Rheumatologists, certification of, 771

## RNA

antibodies to, in SLE, 554  
 of cultured rheumatoid cells, uridine incorporation into, 419  
 protein antigen, in SLE serum, 124  
 reovirus, antibodies to, in SLE, 383, 719

## S

### Salicylates

and enzyme release from leukocytes in phagocytosis, 749  
 genetic control of metabolism of, 550  
 hepatotoxicity in juvenile RA, 1  
 interactions with fenoprofen, 635

### Scanning

brain, in lupus cerebritis, 534  
 of femoral head, in vascularity studies, 539

School achievement, and serum uric acid, 359

### Scleroderma

calcinosis in, 542  
 and effects of cyclophosphamide on lymphocytes, 554  
 finger capillary abnormalities in, 619  
 hemodialysis and kidney transplantation in, 265  
 kidney in, 556  
 pericardial disease in, 559

Serologic data, comparisons of, 701

Shwartzman reaction, induced in 6-sulfanilamidindazole arthritis, 491

Siblings, lupus erythematosus in, 221

### Sjogren's syndrome

in juvenile RA, 122  
 marrow granulocyte reserves in, 345  
 outpatient study of, 574

Skeletal status, in RA, 66

### Skin

experimental lesions resembling SLE, 579  
 immunoglobulin deposits in SLE, 564

### Spine

hyperostosis in Pima Indians, 114  
 intervertebral disc space infections in heroin addicts, 562

### Spondylitis, ankylosing

bowel in, 549  
 genetic studies of, 573  
 and HL-A antigen W27, 568

Staphylococci, acute infectious arthritis from, 547

Sterility rate, and lupus erythematosus, 541

Steroids. *See* Corticosteroids

Still's disease. *See* Rheumatoid arthritis, juvenile

Streptococci, acute infectious arthritis from, 547

6-Sulfanilamidindazole arthritis, and induction of Shwartzman reaction, 491

### Surgery

drainage in acute infectious arthritis, versus medical treatment, 547



- hip replacement, and thromboembolic disease, 117
- knee replacement with prostheses, 532, 533
- partial menisectomy, degenerative lesions after, 397
- reconstruction of rheumatoid wrist, 553
- Synovial cells
  - changes in organ culture, 324
  - cultured JRA, virus replication in, 114
  - prostaglandin synthesis by cultures, colchicine affecting, 129
  - rheumatoid
    - culture of B-immunocytes, 341
    - uridine incorporation into RNA of, 419
- Synovial cysts of elbow, valvular mechanisms in, 259
- Synovial fluid
  - calcium pyrophosphate crystals in, in ochronotic arthropathy, 705
  - cryoglobulins activating alternate pathway of complement, 575
  - detection of trace amounts of, 487
  - immune complexes in, 10
  - inorganic phosphate levels in pseudogout and osteoarthritis, 570
  - lactoferrin in, 186
  - lipid effusion in SLE, 759
  - lymphocytes in early RA, 544
  - proportion of B and T lymphocytes in RA, 138
  - pyrophosphate in, in pseudogout, 171
  - rheumatoid, collagenase affecting cartilage collagen fibrils in, 552
- Synovial membrane
  - acid phosphatase in, and clinical disease, 376
  - in ferritin-induced arthritis, 133
  - in hepatitis, and Australia antigen, 543
  - rheumatoid
    - iron deposition in, 298
    - lymphoid cells in, 471
- Synovitis
  - acute, immunologically induced, 10
  - lymphokine-induced, 121
  - urate crystal-induced, cyclic AMP affecting, 136

## T

- Temporal arteries, immunoglobulins in, 557
- Thoracic duct lymphocytes, drainage in RA, 562
- Thromboembolic disease, and total hip replacement, 117
- Thymocytotoxic antibody, of NZB mice, 561
- Toxoplasmosis, in polymyositis, 555
- Transplantation and hemodialysis of kidney
  - in lupus nephritis, 117
  - in scleroderma, 265
- Tuberculosis
  - and bacterial arthritis, 543
  - with viral hepatitis and SLE, 406
- Tumor development, after cyclophosphamide, 524
- Twins, calcific peri-arthritis in, 393

## U

- Urate crystals
  - with adsorbed endotoxin, and gout induction, 575
  - inducing arthritis, in animals lacking Hageman factor, 571
  - inducing chemotaxis, 571
  - inducing synovitis, cyclic AMP affecting, 136
- Urate sodium
  - binding to serum albumin, 537
  - lysosomal enzyme release by, 132
- Uremia, plasma PPi in, 132
- Uric acid
  - estimation of secretion, 539
  - gouty hyperuricemia, single daily dose of allopurinol in, 128
  - nicotinic acid affecting metabolism of, 545
  - serum levels
    - and achievement in high school, 359
    - glycopyrrolate affecting, 127
    - suppression of secretion in renal hypouricemia, 570
- Uridine incorporation, into RNA of cultured rheumatoid cells, 419
- Urinary metabolites of hydralazine, in SLE, 217

## V

- Valvular disease, rheumatic, pathogenesis of, 122
- Valvular mechanisms, in antecubital cysts in RA, 259
- Vasculitis
  - with monoclonal IgG cryoglobulinemia, 548
  - in rheumatoid arthritis, immunopathogenesis of, 576
- Venography, intraosseous, of osteoarthritic knee, 124
- Viruses
  - antibodies to viral RNA in SLE, 383, 719
  - antibody levels in juvenile RA, 126
  - arthritis from Herpes simplex virus, 241, 533
  - in connective tissue diseases, 125, 677
  - Epstein-Barr virus antibody in SLE, 97
  - in hepatitis with tuberculosis and SLE, 406
  - replication in cultured JRA synovial cells, 114
  - studies in RA, 446
  - studies of uridine incorporation into RNA of cultured rheumatoid cells, 419

## W

- Wegener's granulomatosis, cyclophosphamide in, 657
- Wrist, rheumatoid, reconstruction of, 553

## Y

- Yakima Indians, rheumatoid arthritis in, 743





# arthritis and rheumatism

---

Official Journal of The American Rheumatism Association  
Section of The Arthritis Foundation

---

VOLUME 16, 1973



Medical Department  
HARPER & ROW, PUBLISHERS, INC.  
Hagerstown, Md.

## ARTHRITIS AND RHEUMATISM

### EDITOR

Charles L. Christian, MD

### EDITORIAL BOARD

**K. Frank Austen, MD**, Boston

**J. Claude Bennett, MD**, Birmingham

**John J. Calabro, MD**, Worcester

**Alan S. Cohen, MD**, Boston

**John L. Decker, MD**, Bethesda

**Evelyn V. Hess, MD**, Cincinnati

**David S. Howell, MD**, Miami

**Gene G. Hunder, MD**, Rochester

**William H. Kammerer, MD**, New York

**William N. Kelley, MD**, Durham

**David Koffler, MD**, New York

**Stephen M. Krane, MD**, Boston

**Henry G. Kunkel, MD**, New York

**Henry J. Mankin, MD**, Boston

**Mart Mannik, MD**, Seattle

**William Martel, MD**, Ann Arbor

**Gerald P. Rodnan, MD**, Pittsburgh

**John T. Sharp, MD**, Houston

**Charles D. Tourtellotte, MD**, Philadelphia

**Ralph C. Williams, Jr, MD**, Albuquerque

**Nathan J. Zvaifler, MD**, San Diego

### COMMITTEE FOR THE PUBLICATION OF

#### Arthritis and Rheumatism

**Giles Bole, MD**, Chairman, Ann Arbor

**K. Frank Austen, MD**, Boston

**John S. Davis, MD**, Charlottesville

**John Sharp, MD**, Houston

**J. Donald Smiley, MD**, Dallas

**Norman Talal, MD**, San Francisco

Copyright © 1973 by The Arthritis Foundation, New York, N.Y.

All rights reserved

## CONTENTS

### NO. 1 (JANUARY-FEBRUARY)

Salicylate Hepatotoxicity in Patients with Juvenile Rheumatoid Arthritis <i>Robert R. Rich and John S. Johnson</i>	1
Immunologically Induced Acute Synovitis in Rabbits: Studies of Immune Complexes in Synovial Fluid <i>J. Roger Hollister, George C. Liang and Mart Mannik</i>	10
Experimental Bedsonial Arthritis <i>D. Edwards Smith, Paul G. James, Julius Schachter, Ephraim P. Engleman and Karl F. Meyer</i>	21
Antibiotic Therapy in Experimental Bedsonial Arthritis <i>Robert J. Gilbert, Julius Schachter, Ephraim P. Engleman and Karl F. Meyer</i>	30
Immune Response of Patients with Rheumatoid Arthritis During Cyclophosphamide Treatment <i>John E. Curtis, John T. Sharp, Martin D. Lidsky and Evan M. Hersh</i>	34
An Antibody-Like Material in Systemic Lupus Erythematosus Directed Toward a Thermolabile Serum Macropotein <i>Wallace V. Epstein and Margaret Tan</i>	43
Detection of Circulating DNA by Counterimmunoelectrophoresis (CIE) <i>Gene L. Davis, Jr and John S. Davis, IV</i>	52
An Immunofluorescent Method for the Detection of Antigammaglobulin Antibodies <i>Dorothy Estes, Edgar Atra and André Peltier</i>	59
Skeletal Status in Rheumatoid Arthritis: A Preliminary Report <i>Mark N. Mueller and John M. Jurist</i>	66
The Effect of a Cobra Venom Factor on Complement and Adjuvant-Induced Disease in Rats <i>Lygeri Kourounakis, R.A. Nelson, Jr and M.A. Kupusta</i>	71
<hr/>	
ARA Symposium: Cytotoxic Drugs in Rheumatic Diseases	77-96
Chemical Action and Pharmacology of Methotrexate, Azathioprine and Cyclophosphamide in Man <i>Joseph R. Bertino</i>	79
Immunosuppressive and Antiinflammatory Properties of Cyclophosphamide, Azathioprine and Methotrexate <i>Eric R. Hurd</i>	84
Toxicity of Immunosuppressive Drugs in Man <i>John L. Decker</i>	89

<b>Efficacy of Immunosuppressive Drugs in Rheumatic Diseases</b> <i>Alfred D. Steinberg</i>	<b>92</b>
<b>Epstein-Barr Virus Antibody Levels in Systemic Lupus Erythematosus</b> <i>Paul E. Phillips and Yashar Hirshaut</i>	<b>97</b>
<b>Brief Communication</b> <b>Fender-Kicker Syndrome</b> <i>C. Douglas Angevine, Edward C. Atwater and Ralph F. Jacox</i>	<b>102</b>
<b>ARA Presidential Address</b> <b>The Fortieth</b> <i>J. Sydney Stillman</i>	<b>106</b>
<b>ARA News</b>	<b>112</b>
<b>Abstracts</b>	<b>113</b>

## NO. 2 (MARCH-APRIL)

<b>Treatment of Psoriatic Arthritis With 6-Mercaptopurine</b> <i>John Baum, Eric Hurd, David Lewis, John L. Ferguson and Morris Ziff</i>	<b>139</b>
<b>Double-Blind Study of Cyclophosphamide in Rheumatoid Arthritis</b> <i>Martin D. Lidsky, John T. Sharp and Sharon Billings</i>	<b>148</b>
<b>Cyclophosphamide Therapy in Systemic Lupus Erythematosus and Polymyositis</b> <i>James F. Fries, Gordon C. Sharp, Hugh O. McDevitt and Halsted R. Holman</i>	<b>154</b>
<b>Comparison of Therapeutic and Immunosuppressive Effects of Azathioprine, Prednisolone and Combined Therapy in NZB/NZW Mice</b> <i>Bevra H. Hahn, Mary K. Bagby, Tom R. Hamilton and C. Kirk Osterland</i>	<b>163</b>
<b>Articular Chondrocalcinosis: Microanalysis of Pyrophosphate (PPi) in Synovial Fluid and Plasma</b> <i>Roy D. Altman, Ofelia E. Muniz, Julio C. Pita and David S. Howell</i>	<b>171</b>
<b>Degradation of Proteoglycans in Human Osteoarthritis Cartilage</b> <i>Roy D. Altman, Julio C. Pita and David S. Howell</i>	<b>179</b>
<b>Lactoferrin—An Iron Binding Protein in Synovial Fluid</b> <i>Robert M. Bennett, A. C. Eddie-Quartey and P. J. L. Holt</i>	<b>186</b>
<b>Studies on the Infectious Etiology of Rheumatoid Arthritis</b> <i>B. C. Cole, J. R. Ward and C. B. Smith</i>	<b>191</b>
<b>A Millipore Filter Assay for Antibodies to Native DNA in Sera of Patients with Systemic Lupus Erythematosus</b> <i>Barry Ginsberg and Harold Keiser</i>	<b>199</b>

<b>Mechanisms of Release of Granule Enzymes from Human Neutrophils Phagocytosing Aggregated Immunoglobulin: An Electron Microscopic Study</b> <i>Peter M. Henson</i>	208
<b>Hydralazine Urinary Metabolites in Systemic Lupus Erythematosus</b> <i>Allen Litwin, Louis E. Adams, Evelyn V. Hess, Joseph McManus and Hans Zimmer</i>	217
<b>Report of the Familial Occurrence of Systemic Lupus Erythematosus in Male Siblings</b> <i>David A. Spector, Lee M. Jampol and John P. Hayslett</i>	221
<b>Studies Into the Occurrence of Soluble Antigen-Antibody Complexes in Disease: V. Second Assessment of Correlation Between the Rheumatoid Biologically Active Factor (RBAF) and the Clinical Features of Rheumatoid Arthritis</b> <i>Murray B. Urowitz, Duncan A. Gordan and Irvin Broder</i>	225
<b>Influence of Natural and Synthetic Estrogens on the Course of Autoimmune Disease in the NGB/NZW Mouse</b> <i>Sara Ellen Walker and Giles G. Bole, Jr</i>	231
<b>Experimental Viral Arthritis Induced With Herpes Simplex</b> <i>Francis W. Webb, Rodney Bluestone, Leonard S. Goldberg, Steven D. Douglas and Carl M. Pearson</i>	241
<b>Prostaglandin E<sub>1</sub> (PGE<sub>1</sub>) Suppression of Adjuvant Arthritis: Histopathology</b> <i>Robert B. Zurier and Maurice Ballas</i>	251
<b>Brief Communication</b> <b>Valvular Mechanisms in Antecubital Cysts of Rheumatoid Arthritis</b> <i>George E. Ehrlich and Gad G. Guttmann</i>	259
<b>Arthritis Rounds</b> <b>Hemodialysis and Kidney Transplantation for Renal Failure from Scleroderma</b> <i>James A. Richardson</i>	265
<b>Discussion</b> <i>Gerald P. Rodman</i> <i>E. Carwile LeRoy</i>	268 270
<b><i>Candida guilliermondi</i> Infection of the Knee Complicating Rheumatoid Arthritis: A Case Report</b> <i>D. R. Graham and H. M. Frost</i>	272
<b>Discussion</b> <i>Donald B. Louria</i>	276
<b>Psoriatic Arthritis in a Child</b> <i>C. Douglas Angevine, I. Barry Pless, John Baum and Ralph F. Jacox</i>	278
<b>Discussion</b> <i>Barbara M. Ansell</i> <i>John J. Calabro</i>	281 282
<b>Book Reviews</b> <b>Beyond the Copper Bracelet: What You Should Know About Arthritis</b> <b>Immunology, Immunopathology and Immunity</b>	284 284
<b>ARA News</b>	285

# NO. 3 (MAY-JUNE)

<b>Immunopathologic Significance of Cartilage Antigenic Components in Rheumatoid Arthritis</b> <i>Jerome H. Herman, David W. Willse and Marie V. Dennis</i>	287
<b>Synovial Iron Deposition in Rheumatoid Arthritis</b> <i>Robert M. Bennett, E. D. Williams, S. M. Lewis and P. J. L. Holt</i>	298
<b>The Arthropathy of Hemochromatosis Without Hemochromatosis</b> <i>Duncan A. Gordon and Hugh A. Little</i>	305
<b>Abnormal Structures in Circulating Lymphocytes from Patients with Systemic Lupus Erythematosus and Related Diseases</b> <i>Philip M. Grimley, John L. Decker, Herman J. Michelitch and Molly M. Frantz</i>	313
<b>Fine Structural Analysis of Rabbit Synovial Cells. I. The Normal Synovium and Changes in Organ Culture</b> <i>Phoebe R. Krey and Alan S. Cohen</i>	324
<b>Continuous Culture of a B-Immunocyte from Rheumatoid Synovium</b> <i>Denys K. Ford and J. Donald Smiley</i>	341
<b>Marrow Granulocyte Reserves in the Rheumatic Diseases</b> <i>Harry R. Kimball, Sheldon M. Wolff, Norman Talal, Paul H. Plotz and John L. Decker</i>	345
<b>A Controlled Trial of Gold Salt Therapy in Rheumatoid Arthritis</b> <i>The Cooperating Clinics Committee of the AMERICAN RHEUMATISM ASSOCIATION</i>	353
<b>Serum Uric Acid and Achievement in High School</b> <i>Henry J. Montoye and William M. Mikkelsen</i>	359
<b>Regional Migratory Osteoporosis</b> <i>Ramesh C. Gupta, Mordecai M. Popovtzer, William E. Huffer and Charley J. Smyth</i>	363
<b>Relative T-Cell Specificity of Lymphocytotoxins from Patients with Systemic Lupus Erythematosus</b> <i>Richard B. Lies, Ronald P. Messner and Ralph C. Williams, Jr</i>	369
<b>Correlation of Histochemical, Histologic and Biochemical Evaluations of Human Synovium with Clinical Activity</b> <i>Bruce A. Waxman and Clement B. Sledge</i>	376
<b>Antibodies to Viral and Synthetic Double-Stranded RNA in Discoid Lupus Erythematosus</b> <i>Robert A. Sylvester, Moises Attias, Norman Talal and Denny L. Tuffanelli</i>	383
<b>Polyarthritis and Subcutaneous Nodules Associated with Carcinoma of the Pancreas</b> <i>Arthur M. Virshup and Anthony J. Sliwinski</i>	388



<b>Calcific Periarthritis Involving Multiple Sites in Identical Twins</b> <i>Richard B. Cannon and Frank R. Schmid</i>	393
<b>Experimentally Induced Degenerative Joint Lesions Following Partial Meniscectomy in the Rabbit</b> <i>Roland W. Moskowitz, Wirt Davis, James Sammarco, Mark Martens, Jack Baker, Michael Mayor, A. H. Burstein and V. H. Frankel</i>	397
<b>Serologic Abnormalities in Systemic Lupus Erythematosus Associated with Viral Hepatitis and Tuberculosis</b> <i>Kent W. Salisbury, Paul H. Plotz, Paul V. Holland, Alfred D. Steinberg and Mark Peppercorn</i>	406
<b>Azathioprine in Rheumatoid Arthritis: A Double-Blind, Cross-Over Study</b> <i>Murray B. Urowitz, Duncan A. Gordon, Hugh A. Smythe, Waldemar Pruzanski and Metro A. Ogryzlo</i>	411
<b>Brief Communication</b> <b>Uridine Incorporation into the Media and RNA of Cultured Rheumatoid Synovial Cells</b> <i>Arthur I. Grayzel</i>	419
<b>Current Comment</b> <b>Lymphocyte Heterogeneity and Function</b> <i>Norman Talal</i>	422
<b>Drug Letter</b> <b>Mexicali Treatment of Rheumatoid Arthritis</b> <i>L. A. Healey</i>	426
<b>Letters</b>	428
<b>ARA News</b>	430

#### NO. 4 (JULY-AUGUST)

<b>The Past Four Decades of Progress in the Knowledge of Gout, With an Assessment of the Present Status</b> <i>Alexander B. Gutman</i>	431
<b>Virologic Studies on Rheumatoid Arthritis</b> <i>R. Michael Wilkes, James P. Simsarian, Hope E. Hopps, Henry Roth, John L. Decker, Robert G. Aptekar, and Harry M. Meyer, Jr</i>	446
<b>Differing Effects of Azathioprine and Cyclophosphamide on Immune Responses to Flagellin in Man</b> <i>Ian R. Mackay, John M. Dwyer, and Merrill J. Rowley</i>	455
<b>Bladder Toxicity With Chronic Oral Cyclophosphamide Therapy in Non-malignant Disease</b> <i>Robert G. Aptekar, MD, John P. Atkinson, MD, John L. Decker, MD, Sheldon M. Wolff, MD, and Elizabeth W. Chu, MD</i>	461

<b>Preparation of <math>^{125}\text{I}</math>-Labeled Native DNA for Use in Radioimmunoassays for Anti-Native-DNA Antibodies</b>	
<i>Harold Keiser</i>	468
<b>Electron Microscopic Studies of Lymphoid Cells in the Rheumatoid Synovial Membrane</b>	
<i>Ikuo Kobayashi and Morris Ziff</i>	471
<b>Rapid, Simple Detection of Trace Amounts of Synovial Fluid</b>	
<i>Don L. Goldenberg, Kenneth D. Brandt, and Alan S. Cohen</i>	487
<b>Local and Generalized Shwartzman Reaction Induced in Rats With 6-Sulfanilamidoindazole Arthritis</b>	
<i>John R. Ward, Morgan L. Miller, and Frank Burch</i>	491
<b>Cellular Immunity in Rheumatic Diseases. I. Rheumatoid Arthritis</b>	
<i>Jack Waxman, Michael D. Lockshin, Jerome J. Schnapp, and Ira N. Doneson</i>	499
<b>The Fourth Component of Complement in the Cerebrospinal Fluid in Systemic Lupus Erythematosus</b>	
<i>Nortin M. Hadler, Robert D. Gerwin, Michael M. Frank, John N. Whitaker, Max Baker, and John L. Decker</i>	507
<b>Memorial to Alexander B. Gutman</b>	522
<b>Letters</b>	524
<b>Book Reviews</b>	528
<b>ARA News</b>	530
<b>Abstracts</b>	532

## NO. 5 (SEPTEMBER-OCTOBER)

<b>Experimental Skin Lesions in Mice Resembling Systemic Lupus Erythematosus</b>	
<i>P. G. Natali and E. M. Tan</i>	579
<b>Serum Parathyroid Hormone Levels in Patients With Calcium Pyrophosphate Crystal Deposition Disease (Chondrocalcinosis, Pseudogout)</b>	
<i>Paulding Phelps and Charles D. Hawker</i>	590
<b>Inhibition of Mixed Leukocyte Culture Responses by Serum and <math>\gamma</math>-Globulin Fractions From Certain Patients With Connective Tissue Disorders</b>	
<i>Ralph C. Williams, Jr., Richard B. Lies, and Ronald P. Messner</i>	597
<b>Suppression of Acute and Chronic Inflammation in Adrenalectomized Rats by Pharmacologic Amounts of Prostaglandins</b>	
<i>Robert B. Zurier, Sylvia Hoffstein, and Gerald Weissmann</i>	606
<b>Patterns of Finger Capillary Abnormalities in Connective Tissue Disease by "Wide-Field" Microscopy</b>	
<i>Hildegard Rand Maricq and E. Carwile LeRoy</i>	619

<b>Fenoprofen® Calcium in Rheumatoid Arthritis: A Controlled Double-Blind Cross-over Evaluation</b>	
<i>James F. Fries and Melvin C. Britton</i>	629
<b>Interactions of Aspirin With Nonsteroidal Antiinflammatory Drugs in Man</b>	
<i>Alan Rubin, Bruce E. Rodda, Patricia Warrick, Charles M. Gruber, Jr., and Anthony S. Ridolfo</i>	635
<b>The Effect of Low Oxygen Concentration on Growth, Glycolysis, and Sulfate Incorporation by Articular Chondrocytes in Monolayer Culture</b>	
<i>Ralph E. Marcus</i>	646
<b>The Effect of Cyclophosphamide on Leukocyte Kinetics and Susceptibility to Infection in Patients With Wegener's Granulomatosis</b>	
<i>David C. Dale, Anthony S. Fauci, and Sheldon M. Wolff</i>	657
<b>Destructive Polyarthritis Secondary to <i>Mycobacterium kansasii</i></b>	
<i>Donald E. Girard, Grover C. Bagby, Jr., and John R. Walsh</i>	665
<b>Renal Histology and Clinical Course of Systemic Lupus Erythematosus: A Prospective Study</b>	
<i>Don E. Cheatum, Eric R. Hurd, Stanley W. Strunk, and Morris Ziff</i>	670
<b>A Search for Viruses and Mycoplasmas in Connective Tissue Diseases</b>	
<i>Donald A. Person, John T. Sharp, and William E. Rawls</i>	677
<b>Cell-Mediated Immune Response in Systemic Lupus Erythematosus: <i>In vitro</i> Cellular Response to Native DNA by Macrophage Inhibitory Test</b>	
<i>Tohru Abe, Masako Hara, Kuniomi Yamasaki, and Mitsuo Homma</i>	688
<b>A Fatal Case of Reiter's Disease Complicated by Amyloidosis</b>	
<i>David E. Caughey and Christopher J. Wakem</i>	695
<b>Letters</b>	701
<b>Book Reviews</b>	703
<b>ARA News</b>	704

## NO. 6 (NOVEMBER-DECEMBER)

<b>Ochronotic Arthropathy With Calcium Pyrophosphate Crystal Deposition: A Light and Electron Microscopic Study</b>	
<i>Antonio J. Reginato, H. Ralph Schumacher, and Virginia A. Martinez</i>	705
<b>Adult Onset Juvenile Rheumatoid Arthritis</b>	
<i>Robert G. Aptekar, John L. Decker, Joseph S. Bujak, and Sheldon M. Wolff</i>	715
<b>Filter Radioimmunoassay for Antibodies to Reovirus RNA in Systemic Lupus Erythematosus</b>	
<i>Moises R. Attias, Robert A. Sylvester, and Norman Talal</i>	719

<b>Nucleolar Antigen Specific for Antinucleolar Antibody in the Sera of Patients With Systemic Rheumatic Disease</b> <i>Shoji Miyawaki and Robert F. Ritchie</i>	726
<b>Prevalence of Rheumatoid Arthritis in Alaskan Eskimos</b> <i>R. Palmer Beasley, Henry Retailliau, and L. A. Healey</i>	737
<b>High Prevalence of Rheumatoid Arthritis in Yakima Indians</b> <i>R. Palmer Beasley, Robert F. Willkens, and Peter H. Bennett</i>	743
<b>Mobilization and Extracellular Release of Granular Enzymes From Human Leukocytes During Phagocytosis: Inhibition by Colchicine and Cortisol but Not by Salicylate</b> <i>Daniel G. Wright and Stephen E. Malawista</i>	749
<b>Arthritis Rounds</b> <b>Lipid Synovial Effusion: Unique Occurrence in Systemic Lupus Erythematosus</b> <i>William E. Ryan, Ralph D. Ellefson, and L. Emmerson Ward</i>	759
<b>ARA Presidential Address</b> <b>The Final Common Pathway</b> <i>John L. Decker</i>	765
<b>Editorial</b> <b>Rheumatologists by Certification or by Reputation</b> <i>Joseph Lee Hollander</i>	771
<b>Drug Letter</b> <b>Generic Equivalents</b> <i>L. A. Healey</i>	775
<b>Letters</b>	776
<b>Book Reviews</b>	779
<b>ARA News</b>	781
<b>Annual Indexes</b> <b>Authors</b>	783
<b>Subjects</b>	791

